Comment on the recent PGDIS Position Statement on the Transfer of Mosaic Embryos 2021.

Autor: Murtinger M; Next Fertility IVF Prof. Zech - Bregenz, Bregenz, Austria. maximilian.murtinger@ivf.at., Schuff M; Next Fertility IVF Prof. Zech - Bregenz, Bregenz, Austria., Wirleitner B; Next Fertility IVF Prof. Zech - Bregenz, Bregenz, Austria., Miglar S; Next Fertility IVF Prof. Zech - Salzburg, Salzburg, Austria., Spitzer D; Next Fertility IVF Prof. Zech - Salzburg, Salzburg, Austria.
Jazyk: angličtina
Zdroj: Journal of assisted reproduction and genetics [J Assist Reprod Genet] 2022 Nov; Vol. 39 (11), pp. 2563-2570. Date of Electronic Publication: 2022 Sep 23.
DOI: 10.1007/s10815-022-02620-y
Abstrakt: The worldwide demand of preimplantation genetic testing for aneuploidy (PGT-A) is still growing. However, chromosomal mosaic results greatly challenge the clinical practice. The recently published PGDIS Position Statement on the Transfer of Mosaic Embryos is the third PGDIS position statement on how to deal with embryos diagnosed as chromosomal mosaics (CM) and, one of many attempts of different societies and working groups to provide a guideline for clinicians, laboratories, clinics, and genetic counselors. But still, as in previous statements, many issues remained unresolved. Moreover, from our point of view, the question how to deal with embryos diagnosed as CM, consisting of two or more karyological cell lines cannot be separated from all the other aspects of PGT-A including its accuracy. The paucity of clearcut indications for PGT-A and evidence of benefit as well as an overall cost-benefit assessment is given below.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: